奥沙利铂联合卡培他滨治疗晚期结肠癌的临床研究  

Clinical trial of oxaliplatin combined with capecitabine in the treatment of advanced colon cancer

作　　者：毛跃伟[1] 杨松鹏[1] 高磊[1] 胡德升[1] 尹宁伟[1] 刘寒松[1] 

机构地区：[1]郑州大学附属郑州中心医院胃肠血管外科,郑州450000

出　　处：《中国临床药理学杂志》2016年第14期1286-1288,1292,共4页The Chinese Journal of Clinical Pharmacology

基　　金：河南省医学科技攻关计划基金资助项目(201203047)

摘　　要：目的观察奥沙利铂联合卡培他滨治疗晚期结肠癌的临床疗效及安全性。方法将40例晚期结肠癌患者随机分为对照组20例和试验组20例。对照组予以静脉滴注130 mg·m^(-2)奥沙利铂,第1天+静脉滴注500 mg·m-2氟尿嘧啶,第1~5天,14 d为1个周期,共治疗3个周期;试验组予以静脉滴注130mg·m^(-2)奥沙利铂,第1天+口服1250 mg·m^(-2)卡培他滨,第1~14天,21 d为1个周期,共治疗2个周期。比较2组患者的临床疗效、血清卵巢癌缺失基因蛋白、癌基因ras产物P21蛋白、原癌基因蛋白以及白细胞介素-6,以及不良反应发生率。结果治疗后,试验组的总有效率为85.00%(17/20例)显著高于对照组的45.00%(9/20例,P<0.05)。治疗后,试验组的血清巢癌缺失基因蛋白水平为(25.65±3.14)μg·m L^(-1)明显高于对照组的(17.45±2.27)μg·m L^(-1)。治疗后,试验组与对照组的血清癌基因ras产物P21蛋白分别为(8.54±1.23),(15.67±2.11)ng·m L^(-1);原癌基因蛋白分别为(1.76±1.15),(19.54±2.31)ng·m L^(-1);白细胞介素-6分别为(108.62±10.77),(122.45±14.25)pg·m L^(-1),差异有统计学意义(P<0.05)。试验组和对照组的不良反应以神经系统、消化系统和皮肤系统的症状为主,其发生率分别为15.00%和30.00%,差异无统计学意义(P>0.05)。结论奥沙利铂联合卡培他滨治疗晚期结肠癌的临床疗效显著,能显著降低结肠癌患者血清癌基因ras产物P21蛋白、原癌基因蛋白及白细胞介素-6水平,促进巢癌缺失基因蛋白表达,安全性较高。Objective To evaluate the clinical efficacy and safety of oxaliplatin combined with capecitabine in the treatment of advanced colon cancer. Methods A total of 40 patients with advanced colon cancer were randomly divided into control group（ n = 20） and treatment group（ n = 20）. Control group was given 130 mg·m（- 2） oxaliplatin,intravenous infusion,day 1 and 500 mg · m（- 2） fluorouracil,intravenous infusion,days 1- 5,for three cycles with 14 days per cycle. Treatment group was treated with 130 mg · m（- 2） oxaliplatin,intravenous infusion,day 1 and 1250 mg·m（- 2） capecitabine,days 1^-14,for two cycles with 21 days per cycle. The clinical efficacy,levels of serum ovarian cancer gene protein,oncogene Ras product P21 protein,proto oncoprotein and interleukin 6,the incidence of adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control group were 85. 00%（ 17 /20）,45. 00%（ 9 /20）,respectively,with statistically significant difference（ P〈0. 05）. Aftertreatment,the level of serum ovarian cancer gene protein in treatment group was significantly higher than that in control group [（ 25. 65 ± 3. 14） vs（ 17. 45 ± 2. 27） μg·m L^-1,P〈0. 05]. After treatment,among the treatment and control group,the levels of serum oncogene Ras product P21 protein were（ 8. 54 ± 1. 23）,（ 15. 67 ± 2. 11） ng·m L^-1,proto oncoprotein were（ 1. 76 ± 1. 15）,（ 19. 54 ± 2. 31） ng·m L^-1and the levels of interleukin 6 were（ 108. 62 ± 10. 77）,（ 122. 45 ± 14. 25） pg·m L^-1,also,the indexes in treatment group after treatment were significantly lower than those in control group（ P〈0. 05）. The adverse drug reactions were based on the symptoms of nervous system,digestive system and skin for two groups. Also,the incidence of adverse drug reactions in control group was 30. 00%,treatment group was 15. 00%,the difference had no statistically significant difference（ P〉0. 05）. Conclusion Oxaliplati

关 键 词：奥沙利铂 卡培他滨 结肠癌 安全性 

分 类 号：R979.1[医药卫生—药品]